Pidomode oral solution, a 6-class generic drug of Dikang Pharmaceutical Co., Ltd., will soon be approved for production
-
Last Update: 2014-11-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Dikang pharmaceutical insiders confirmed that the product company plans to serve as a processing agent, not as a key product Pidomode oral solution is an immunomodulator, which is suitable for patients with low immune function It mainly treats acute bronchitis, rhinitis, sinusitis, otitis media, pharyngitis, etc In addition to the original research drug "primo", at present, only Jiangsu Wuzhong (600200 SH) produces pidomode oral solution in China According to the annual report data released by Wuzhong, Jiangsu Province, pidomode oral solution (trade name: fuluyin) achieved sales revenue of 729 million yuan and operating profit (gross profit) of 223 million yuan in 2013 Dikang pharmaceutical mainly focuses on drugs and biomedical devices, involving drug research and development, drug marketing, drug chain operation and other businesses According to the annual report of 2013, the company achieved an annual operating revenue of 377 million yuan, a year-on-year increase of 3.27%; and a net profit of 22.5286 million yuan, a year-on-year increase of 5.09%.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
